Schedules of Nab-Paclitaxel in Metastatic Breast Cancer (SNAP)
A Randomized Phase II Study Evaluating Different Schedules of Nab-Paclitaxel in Metastatic Breast Cancer (SNAP Trial)
Sponsor: Breast International Group
This PHASE2 trial investigates Metastatic Breastcancer and is currently completed. Breast International Group leads this study, which shows 12 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2022 — Jul 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Oct 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE2
-
Apr 2021 — Oct 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Breast International Group
- ETOP IBCSG Partners Foundation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarau, Switzerland , Alessandria, Italy , Barcelona, Spain , Basel, Switzerland , Bellinzona, Switzerland , Bern, Switzerland , Biel, Switzerland , Biella, Italy , Castellanza, Italy , Castelló, Spain and 25 more locations